Clinipace

Clinipace has revamped its eClinical data platform, TEMPO, saying its new offering rolls disparate IT applications into one, allowing clients to cut down the cost and complexity of their clinical trials.

A month after doubling in size with its buyout of Paragon Biomedical, Clinipace has raised $9 million to flesh out its workforce.

Clinipace has struck a deal to acquire California's Paragon Biomedical, a move the CRO says will boost its therapeutic expertise and expand its footprint around the world.

CRO Clinipace is providing electronic data capture, clinical monitoring, site management, biostatistical consulting and regulatory document management for Inspire Pharmaceuticals for Phase 2 clinical